Jim Greenwood CEO BIO: Addressing the need for internationally consistent IP standards.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Jim Greenwood CEO BIO: Addressing the need for internationally consistent IP standards.
Released on: September 17, 2015. © PharmaVentures Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    It is essential for governments that want to foster a robust biotech innovation environment to create a set of strong IP standards, particularly those governing data protection, patents and trade secret protection, which are relevant to biological products.
  • Summary
  • Transcript
  • Participants
  • Company
It is essential for governments that want to foster a robust biotech innovation environment to create a set of strong IP standards, particularly those governing data protection, patents and trade secret protection, which are relevant to biological products. Jim Greenwood, CEO of BIO talks to Fintan Walton, CEO of PharmaVentures about how they are addressing this, as well as the other challenges faced by the bio-pharna Industry.
It is essential for governments that want to foster a robust biotech innovation environment to create a set of strong IP standards, particularly those governing data protection, patents and trade secret protection, which are relevant to biological products. Jim Greenwood, CEO of BIO talks to Fintan Walton, CEO of PharmaVentures about how they are addressing this, as well as the other challenges faced by the bio-pharna Industry.
It is essential for governments that want to foster a robust biotech innovation environment to create a set of strong IP standards, particularly those governing data protection, patents and trade secret protection, which are relevant to biological products. Jim Greenwood, CEO of BIO talks to Fintan Walton, CEO of PharmaVentures about how they are addressing this, as well as the other challenges faced by the bio-pharna Industry.
Biotechnology Industry Organization (BIO)
BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. Corporate members range from entrepreneurial companies developing a first product to Fortune 500 multinationals.